Erlotinib-Associated Rash Exacerbated by Whole-Brain Radiation Therapy: A Patient's Case Report

Pract Radiat Oncol. 2019 May;9(3):128-131. doi: 10.1016/j.prro.2018.12.007. Epub 2019 Feb 13.

Authors

Alexander K Erikson¹, Nathan Y Yu¹, Janina T Sheedy¹, Staci N Shoudis¹, Harshita R Paripati², Terence T Sio³

Affiliations

¹ Department of Radiation Oncology, Mayo Clinic Arizona, Phoenix, Arizona.
² Department of Medical Oncology, Mayo Clinic Arizona, Phoenix, Arizona.
³ Department of Radiation Oncology, Mayo Clinic Arizona, Phoenix, Arizona. Electronic address: [email protected].

PMID: 30770236
DOI: 10.1016/j.prro.2018.12.007

No abstract available

Publication types

Case Reports

MeSH terms

Adenocarcinoma of Lung / genetics
Adenocarcinoma of Lung / secondary
Adenocarcinoma of Lung / therapy
Aged
Antineoplastic Agents / adverse effects*
Brain Neoplasms / genetics
Brain Neoplasms / secondary
Brain Neoplasms / therapy
Chemoradiotherapy / adverse effects
Chemoradiotherapy / methods
Cranial Irradiation / adverse effects*
Cranial Irradiation / methods
Disease Progression
Drug Eruptions / drug therapy
Drug Eruptions / etiology*
ErbB Receptors / antagonists & inhibitors
ErbB Receptors / genetics
Erlotinib Hydrochloride / adverse effects*
Exanthema / drug therapy
Exanthema / etiology*
Face
Female
Humans
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Lung Neoplasms / therapy
Radiodermatitis / drug therapy
Radiodermatitis / etiology*
Skin / drug effects
Skin / radiation effects
Treatment Outcome

Substances

Antineoplastic Agents
Erlotinib Hydrochloride
EGFR protein, human
ErbB Receptors